RHEUMATOID ARTHRITIS PRICING, REIMBURSEMENT & MARKET ACCESS 2018

Tuesday, May 8, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 8, 2018 /PRNewswire/ -- Report DetailsThis report provides analysis and evaluation of the current and

potential economic burden of Rheumatoid Arthritis (RA) in the major regions of the world comprising North America, Europe (EU5), Asia-Pacific and BRIC
markets. The report also outlines the historical and current healthcare status for the selected markets with respect to the expenditures and the health system that govern medical access. With the increased competition in the RA market resulting from the biosimilar race and new biologic entrants such as the JAK inhibitors and IL-6 inhibitors, payers now have the leverage to enact on the cost-containment of the drug category that has been experiencing high unit cost increases year after year. The blockbuster drugs of the anti-TNF category such as, Humira and Enbrel along with Remicade have been the market leaders in RA treatment since their launch however the rising biosimilars especially to Remicade and Enbrel are posing threats to their global market shares.Read the full report: https://www.reportlinker.com/p05389576 How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.In this brand new report you find 333-page report you will receive 53 tables and 88 figures– all unavailable elsewhere.The 333-page report provides clear detailed insight into the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. Discover the key drivers and challenges affecting the market.By ordering and reading our brand new report today you stay better informed and ready to act.Report Scope• Provides a brief history of rheumatoid arthritis, treatment options, marketed drugs and pipeline products.• Discusses the global pricing & reimbursement for therapeutic drugs, factors affecting pricing & reimbursement, price negotiations & discounts and reimbursement policies.• Discusses Health Economics and Outcomes Research (HEOR), Economic Value Planning, Cost-Effectiveness analysis as well as patent expiry and effects on pricing.• Discusses Health Technology Assessment (HTA) in market access, key benefits of HTA, HTA regulatory agencies.Discusses the healthcare system, healthcare expenditure, key formularies, role of pharmacists, regulatory & approval process, pricing & reimbursement process, HTA, cost of rheumatoid arthritis treatment and payer insight, of these national markets:• The US• CanadaUnited KingdomGermanyFranceItalySpainJapanAustraliaBrazilRussiaIndiaChina• Discusses parallel import in the US and EuropeRead the full report: https://www.reportlinker.com/p05389576 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/rheumatoid-arthritis-pricing-reimbursement--market-access-2018-300642849.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store